Approved for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test (tissue or plasma specimen) — an oncogenic driver mutation found in roughly 3–4% of newly diagnosed NSCLC.